



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

FEB 1 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Cheryl G. Dyer
Regulatory Compliance Specialist
Chattanooga Group, Inc.
4717 Adams Road
P.O. Box 489
Hixson, Tennessee 37343-0489

Re: K982317
Trade Names: Vectra 2C and Vectra 4C
Product Codes: GZJ, LIH, IPF, IMG, and IMI
K982321
Trade Names: Vectra 2S and Vectra 4S
Product Codes: GZJ, LIH, and IPF
K982324
Trade Names: Vectra Pro 2 and Vectra Pro 4
Product Codes: GZJ, LIH, IPF, IMG, and IMI
Regulatory Class: II
Dated: December 10, 1999
Received: December 11, 1999

Dear Ms. Dyer:

We have reviewed your Section 510(k) notifications of intent to market the devices referenced above and we have determined these devices are substantially equivalent (for the indications for use stated in the enclosures) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your devices are classified (see above) into either class II (Special Controls) or class III (Premarket Approval), they may be subject to such additional controls. Existing major regulations affecting your devices can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory

action. In addition, FDA may publish further announcements concerning your devices in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your devices as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your devices to legally marketed predicate devices results in a classification for your devices and thus, permits your devices to proceed to the market.

If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your devices, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

for Mark N. Milbrink
Celia M. Witten, Ph.D., M.D.

Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosures

K982321



INDICATIONS

For VMS, Russian, Monophasic Hi-Volt

- Relaxation of muscle spasms
- Prevention or retardation of disuse atrophy
- Increasing local blood circulation
- Muscle re-education
- Maintaining or increasing range of motion
- Immediate postsurgical stimulation of calf muscles to prevent venous thrombosis

For Microcurrent, Interferential and Premodulated

- Symptomatic relief of chronic, intractable pain
- Management of pain associated with post-traumatic or post-operative conditions

Mark N. Melkerson

for

(Division Sign-Off)

Division of General Restorative Devices

510(k) Number K982321

Prescription Use X
(Per 21 CFR 801.109)

4717 Adams Road
P.O. Box 489
Hixson, TN 37343-0489
Phone: 423-870-2281
Fax: 423-870-7404